Loading clinical trials...
Loading clinical trials...
Effect of Individual Cognitive Stimulation on Memory and Executive Functioning in Older Adults With Mild to Moderate Alzheimer's Disease: A Multicentre Randomised Controlled Trial
This multicentre study, with a randomised controlled repeated measures experimental design, will be conducted in several Portuguese institutions, which provide care and supportive services for older adults diagnosed with mild or moderate Alzheimer's disease (AD), with an aim to assess the effect of individual cognitive stimulation (CS) on memory and executive functioning. Participants in the intervention group will attend 24 individual CS sessions, twice weekly for 12 weeks. Participants in the control group will complete their usual routines without any activity restrictions.
Neurocognitive disorders (NCD) currently affect around 55 million people worldwide and expected to increase to 78 million by 2030 and 139 million by 2050, with Alzheimer's disease (AD) potentially accounting for 60-70% of dementia cases. Dementia is a syndrome, generally chronic or progressive in nature, that causes deterioration of cognitive function, particularly memory and executive functions, beyond what is expected in normal aging. However, there is evidence that in the early stages of NCD, people can learn and improve their cognitive functions through interventions such as CS. CS is a psychosocial intervention and a non-pharmacological therapy recommended by international practice guidelines for people with mild-to-moderate stage AD. However, it is also important to investigate whether NCD generates new skills or only preserves acquired skills, given that AD manifests initially and notably with deficits in memory and learning, sometimes accompanied by deficits in executive functions. Testing the effectiveness of CS by recruiting a representative sample from several Portuguese districts and using a CS programme with detailed and comprehendible content, may elicit relevant evidence in clinical practice, contribute to the development of social development programs and initiatives to ensure social protection and inclusion, promote recurrent therapeutic interventions in Portuguese institutions with provide care and supporting services for older adults with dementia, and strengthen research on non-pharmacological therapies. Thus, this multicentre, randomised controlled study is essential to analyse the effects of the individual CS on global cognitive function and specific cognitive domains (e.g., executive functioning, memory) in older adults with mild or moderate AD.
Age
65 - No limit years
Sex
ALL
Healthy Volunteers
No
Rsocialform - Geriatria, Lda
Mealhada, Aveiro District, Portugal
Santa Casa da Misericórdia da Horta
Açores, Portugal
Cediara - Associação de Solidariedade Social de Ribeira de Fráguas
Aveiro, Portugal
Centro Social e Cultural S. Pedro de Bairro
Braga, Portugal
Centro Social Vale do Homem - Casa da Alegria
Braga, Portugal
Santa Casa da Misericórdia de Castro Marim
Faro, Portugal
Fundação João Bento Raimundo
Guarda, Portugal
Santa Casa da Misericórdia de Alcobaça
Leiria, Portugal
Associação de Socorros da Freguesia de Turcifal
Lisbon, Portugal
Centro de Apoio Social de Oeiras - IASFA
Lisbon, Portugal
Start Date
July 1, 2022
Primary Completion Date
March 31, 2023
Completion Date
October 6, 2023
Last Updated
October 16, 2023
142
ACTUAL participants
Cognitive stimulation
BEHAVIORAL
Lead Sponsor
Rsocialform - Geriatria, Lda
Collaborators
NCT07220668
NCT06154174
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04246437